Emory University

Chimerix, Inc.

Other

University of California

Gilead Sciences, Inc.

Triangle Pharmaceuticals, Inc.

Burroughs Wellcome Co.

Dennis C. Liotta

George R. Painter

Jose Soria

Merrick Almond

Marcos Sznaidman

Darryl Cleary

George R Painter

Merrick R Almond

Gregory R Bluemling

Dennis C Liotta

Abel De La Rosa

David Brian Guthrie

Darryl G Cleary

Michael G Natchus

Phillip A Furman

Jos&egrave; D Soria

Karl Y Hostetler

James R Beadle

Timothy A Riley

David Walter Barry

Franck Rousseau

Jacqueline Ruiz

Paula Francom

Amir Pesyan

Ernest Randall Lanier, Jr

Damien Kuiper

Alexander Kolykhalov

Darryl G Gleary

José D Soria

Michael R Natchus

Marcos L Sznaidman

Ernest Randall Lanier

This disclosure related to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the nucleotide or nucleoside is a compound having the formula:

Substituted nucleosides and nucleotides for treating viral infections

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.

N4-hydroxycytidine and derivatives and anti-viral uses related thereto

This disclosure relates therapeutic compositions containing a compound of Formula Im: or a pharmaceutically acceptable salt thereof, wherein Ris as defined herein.

Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections

This disclosure relates to N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment and prophylaxis of viral infections.

Disclosed are compounds and compositions to the treatment of infectious diseases and methods of treating such diseases. The compounds and compositions include derivatives of clevudine. The compounds and compositions include derivatives of clevudine in combination with another antiviral agent. The compounds and compositions include derivatives of clevudine in combination with a phosphoramidate of lamivudine, adefovir, tenofovir, telbivudine, entecavir, or combinations thereof.

Phosphoramidates for the treatment of hepatitis B virus

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the nucleotide or nucleoside is defined by Formula I below, 

Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating viral infections, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether. The nucleotide or nucleoside is defined by Formula Ia below: 

Substituted nucleotides and nucleosides for treating viral infections

This disclosure relates to certain N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of a Zika virus infection.

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Nucleotide and nucleoside therapeutic compositions and uses related thereto

The present invention provides methods of treating human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, including administering a compound described in the invention in an amount effective treat the HIV and/or HBV infection and at least substantially inhibit the development of resistance to said antiviral compounds in the subject. Pharmaceutical compositions are also provided.

Methods of treating viral infections

The present application provides methods and compositions for combination therapy with antiviral compounds for the treatment of poxvirus infections, such as orthopox virus infections. In one embodiment, a method of treatment of a poxvirus infection is provided that comprises administering to a host in need thereof cidofovir, cyclic cidofovir, or a salt, ester, or prodrug thereof in combination or alternation with at least a second anti-poxvirus agent. The second anti-poxvirus agent is, for example, a biologic, such as a pegylated interferon.

Compounds, compositions and methods for the treatment of poxvirus infections

The present invention provides methods of treating viral infection of the eye or posterior ocular condition including administering a pharmaceutical composition comprising a compound described in the present application. In some embodiments, the pharmaceutical composition is topically administered. In another embodiment, the pharmaceutical composition is orally administered or intraocularly administered.

Compounds, compositions and methods for treating ocular conditions

This application provides a process for preparing enantiomerically pure &#x3b2;-D-dioxolane nucleosides. In particular, a new synthesis of (&#x2212;)-DAPD, suitable for large scale development, is described. In one embodiment the invention provides a process for preparing a substantially pure &#x3b2;-D- or &#x3b2;-L-1,3-dioxolane nucleosides comprising a) preparing or obtaining an esterified 2,2-dialkoxy ethanol; b) cyclizing the esterified 2,2-dialkoxy ethanol with glycolic acid to obtain a 1,3-dioxolane lactone; c) resolving the 1,3-dioxolane lactone to obtain a substantially pure D- or L-lactone; d) selectively reducing and activating the D- or L-chiral lactone to obtain a substantially pure D- or L-1,3-dioxolane; e) coupling the D- or L-1,3-dioxolane to an activated and/or protected purine or pyrimidine base; and f) optionally purifying the nucleoside to obtain a substantially pure protected &#x3b2;-D- or &#x3b2;-L-1,3-dioxolane nucleoside.

Growing community of inventors

Chapel Hill, NC, United States of America

George R Painter